Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
The safety and immunogenicity profiles of Ad26.COV2.S support further development of this vaccine candidate. (Funded by Johnson & Johnson and the Biomedical Advanced Research an...